RRM2 Polyclonal antibody
RRM2 Polyclonal Antibody for WB, IHC, IF/ICC, FC (Intra), IP, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human and More (2)
Applications
WB, IHC, IF/ICC, FC (Intra), IP, CoIP, ELISA
Conjugate
Unconjugated
Cat no : 11661-1-AP
Synonyms
Validation Data Gallery
Tested Applications
| Positive WB detected in | HeLa cells, A431 cells, HUVEC cells, K-562 cells |
| Positive IP detected in | K-562 cells |
| Positive IHC detected in | human tonsillitis tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HepG2 cells |
| Positive FC (Intra) detected in | HepG2 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:6000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| Flow Cytometry (FC) (INTRA) | FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 11 publications below |
| IHC | See 5 publications below |
| IF | See 2 publications below |
| CoIP | See 1 publications below |
Product Information
11661-1-AP targets RRM2 in WB, IHC, IF/ICC, FC (Intra), IP, CoIP, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse, chicken |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | RRM2 fusion protein Ag2203 相同性解析による交差性が予測される生物種 |
| Full Name | ribonucleotide reductase M2 polypeptide |
| Calculated molecular weight | 389 aa, 45 kDa |
| Observed molecular weight | 45 kDa |
| GenBank accession number | BC030154 |
| Gene symbol | RRM2 |
| Gene ID (NCBI) | 6241 |
| RRID | AB_2180392 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Ribonucleotide reductase M2 subunit is one of two subunits that constitute ribonucleotide reductase, the enzyme that catalyzes the conversion of ribonucleotide 5'-diphosphates into 2'-deoxyribonucleotides, a rate-limiting step in the production of 2'-deoxyribonucleoside 5'-diphosphates (dNTP) required for DNA synthesis and repair that is required for DNA synthesis and repair [PMID:20825972, 19250552]. RRM2 is only expressed during the late G1/early S phase, and degraded in late S phase, and the activity of RNR, and therefore DNA synthesis and cell proliferation, is controlled during the cell cycle by the synthesis and degradation of RRM2 subunit [PMID:3894352].
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for RRM2 antibody 11661-1-AP | Download protocol |
| IHC protocol for RRM2 antibody 11661-1-AP | Download protocol |
| IF protocol for RRM2 antibody 11661-1-AP | Download protocol |
| IP protocol for RRM2 antibody 11661-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Cell Rep The mechano-chemical circuit in fibroblasts and dendritic cells drives basal cell proliferation in psoriasis | ||
Oxid Med Cell Longev lncRNA IGF2-AS Regulates Nucleotide Metabolism by Mediating HMGA1 to Promote Pyroptosis of Endothelial Progenitor Cells in Sepsis Patients. | ||
Front Cell Dev Biol A Novel Ferroptosis-Based Molecular Signature Associated with Biochemical Recurrence-Free Survival and Tumor Immune Microenvironment of Prostate Cancer. | ||
Antiviral Res Long-term HIV-1 infection induces an antiviral state in primary macrophages. | ||
Front Oncol Novel Prognostic Signatures of Hepatocellular Carcinoma Based on Metabolic Pathway Phenotypes. | ||
Biomed Pharmacother Identification of osalmid metabolic profile and active metabolites with anti-tumor activity in human hepatocellular carcinoma cells. |
